Attovia Therapeutics 在IPO規模擴大至2.89億美元后，有望在納斯達克上市首日大漲

路透中文

08/05

BUZZ-<a href="https://laohu8.com/S/ATTO">Attovia Therapeutics</a> 在IPO規模擴大至2.89億美元后，有望在納斯達克上市首日大漲

8月5日 - ** 阿托維亞治療公司（Attovia Therapeutics，股票代碼： ATTO.O）在將美國首次公開募股（IPO）規模擴大至2.89億美元后，其納斯達克首日上市開盤價有望遠高於發行價

** 該股最新顯示開盤價為每股24美元，而IPO發行價為17美元

** 總部位於加利福尼亞州聖卡洛斯的 ATTO（(link)）於周二晚間以每股17美元的價格售出1700萬股 (link)，此次IPO規模已擴大 (link)

** ATTO公司致力於研發免疫介導性疾病的治療方案，最初計劃發行約1250萬股，定價區間為每股15至17美元

** 其主要研發項目包括ATTO-1310，該藥物正在開發用於治療慢性瘙癢性疾病

** 摩根士丹利、Leerink Partners、花旗集團和加拿大皇家銀行資本市場擔任此次發行的聯合簿記管理人

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/2657452303"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2657452303\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2657452303?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2026-08-05 22:53","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2657452303","market":"us","top_or_hot":-1,"title":"Attovia Therapeutics 在IPO規模擴大至2.89億美元后，有望在納斯達克上市首日大漲","media":"路透中文","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-<a href=\"https://laohu8.com/S/ATTO\">Attovia Therapeutics</a> 在IPO規模擴大至2.89億美元后，有望在納斯達克上市首日大漲</title></head><body><p><span>8月5日</span><span> - </span>** 阿托維亞治療公司（Attovia <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>，股票代碼： <span>ATTO.O</span>）在將美國首次公開募股（IPO）規模擴大至2.89億美元后，其納斯達克首日上市開盤價有望遠高於發行價 </p><p>** 該股最新顯示開盤價為每股24美元，而IPO發行價為17美元</p><p>** 總部位於加利福尼亞州聖卡洛斯的 ATTO（(<span>link</span>)）於周二晚間以每股17美元的價格售出1700萬股 (link)，此次IPO規模已擴大 (<span>link</span>) </p><p>** ATTO公司致力於研發免疫介導性疾病的治療方案，最初計劃發行約1250萬股，定價區間為每股15至17美元</p><p>** 其主要研發項目包括ATTO-1310，該藥物正在開發用於治療慢性瘙癢性疾病</p><p>** <a href=\"https://laohu8.com/S/MS\">摩根士丹利</a>、Leerink Partners、<a href=\"https://laohu8.com/S/C\">花旗集團</a>和<a href=\"https://laohu8.com/S/RY\">加拿大皇家銀行</a>資本市場擔任此次發行的聯合簿記管理人</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Attovia Therapeutics 在IPO規模擴大至2.89億美元后，有望在納斯達克上市首日大漲</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAttovia Therapeutics 在IPO規模擴大至2.89億美元后，有望在納斯達克上市首日大漲\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1098195322\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">路透中文 </p>\n<p class=\"h-time smaller\">2026-08-05 22:53</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-<a href=\"https://laohu8.com/S/ATTO\">Attovia Therapeutics</a> 在IPO規模擴大至2.89億美元后，有望在納斯達克上市首日大漲</title></head><body><p><span>8月5日</span><span> - </span>** 阿托維亞治療公司（Attovia <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>，股票代碼： <span>ATTO.O</span>）在將美國首次公開募股（IPO）規模擴大至2.89億美元后，其納斯達克首日上市開盤價有望遠高於發行價 </p><p>** 該股最新顯示開盤價為每股24美元，而IPO發行價為17美元</p><p>** 總部位於加利福尼亞州聖卡洛斯的 ATTO（(<span>link</span>)）於周二晚間以每股17美元的價格售出1700萬股 (link)，此次IPO規模已擴大 (<span>link</span>) </p><p>** ATTO公司致力於研發免疫介導性疾病的治療方案，最初計劃發行約1250萬股，定價區間為每股15至17美元</p><p>** 其主要研發項目包括ATTO-1310，該藥物正在開發用於治療慢性瘙癢性疾病</p><p>** <a href=\"https://laohu8.com/S/MS\">摩根士丹利</a>、Leerink Partners、<a href=\"https://laohu8.com/S/C\">花旗集團</a>和<a href=\"https://laohu8.com/S/RY\">加拿大皇家銀行</a>資本市場擔任此次發行的聯合簿記管理人</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0882574139.USD","symbol_name":"富達環球消費行業基金A ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nL4T4421TN:1","article_id":"2657452303","we_media_id":"1098195322","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2657452303","pubTimestamp":1785941615,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"路透中文","introduction":"路透中文","home_visible":1,"id":"1098195322","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-Attovia Therapeutics 在IPO規模擴大至2.89億美元后，有望在納斯達克上市首日大漲8月5日-** 阿托維亞治療公司（Attovia Therapeutics，股票代碼：ATTO.O）在將美國首次公開募股（IPO）規模擴大至2.89億美元后，其納斯達克首日上市開盤價有望遠高於發行價** 該股最新顯示開盤價為每股24美元，而IPO發行價為17美元** 總部位於加利福尼亞","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU0882574139.USD":"富达环球消费行业基金A ACC","LU1668664300.SGD":"Blackrock World Financials A2 SGD-H","KBWB":"银行ETF-PowerShares","LU2125154778.USD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (USD) INC","LU1244550494.USD":"FRANKLIN GLOBAL MULTI-ASSET INCOME \"A\" (USDHEDGED) ACC","LU0130102774.USD":"Natixis Harris Associates US Equity RA USD","LU1162221912.USD":"FRANKLIN INCOME \"A\" (USD) ACC","BK4504":"桥水持仓","BK4207":"综合性银行","LU0162691827.USD":"BGF US BASIC VALUE \"A4\" INC","FTXO":"First Trust Nasdaq Bank ETF","LU2417539215.USD":"ALLIANZ GLOBAL INCOME \"AMF\" (USD) INC","LU0128525689.USD":"TEMPLETON GLOBAL BALANCED \"A\"(USD) ACC","LU0203347892.USD":"SCHRODER ISF QEP GLOBAL ACTIVE VALLUE \"A\" (USD)  INC AV","LU2271345857.HKD":"ALLIANZ GLOBAL SUSTAINABILITY \"AT\" (HKD) ACC","BK4581":"高盛持仓","LU2125154935.USD":"ALLSPRING (LUX) WF GLOBAL EQUITY ENHANCED INCOME \"I\" (USD) INC","LU2111349929.HKD":"ALLIANZ GLOBAL SUSTAINABILITY \"AM\" (HKD) INC","LU0052756011.USD":"TEMPLETON GLOBAL BALANCED \"A\" (USD) INC","LU1363072403.SGD":"Fidelity Global Financial Services A-ACC-SGD","LU0310800965.SGD":"FTIF - Templeton Global Balanced A Acc SGD","MNSH":"MNSN HLDGS INC.","LU0098860793.USD":"FRANKLIN INCOME \"A\" INC","LU1989772840.SGD":"CPR Invest - Climate Action A2 Acc SGD-H","LU0203345920.USD":"SCHRODER ISF QEP GLB ACT. VL \"A\" (USD) ACC","LU1791710400.SGD":"Fidelity Global Demographics A-ACC-SGD","LU1732800096.USD":"摩根大通环球收益基金A (irc)","LU1791807156.HKD":"BGF WORLD FINANCIALS \"A2\" (HKDHDG) ACC","IYF":"金融指数ETF-iShares Dow Jones","LU0158827948.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"A\" (USD) INC","LU1720051108.HKD":"ALLIANZ GLOBAL ARTIFICIAL INTELLIGENCE \"AT\" (HKD) ACC","LU2487616109.SGD":"JPM AMERICA EQUITY \"A\" (SGD) ACC","BK4566":"资本集团","TFNS":"T. Rowe Price Financials ETF","LU0528227936.USD":"富达环球人口趋势基金A-ACC","LU2028103732.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"AMG\" (USD) INC","ATTO":"Attovia Therapeutics","IE00B3S45H60.SGD":"Neuberger Berman US Multicap Opportunities A Acc SGD-H","LU2089283258.USD":"安联环球可持续基金Cl AM Dis","LU1244550221.USD":"FRANKLIN GLOBAL MULTI-ASSET  INCOME \"A\" (USDHEDGED) INC (M)","LU2357305700.SGD":"Allianz Global Artificial Intelligence ET H2-SGD","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","LU1791710582.SGD":"Fidelity Global Demographics A-ACC-SGD (SGD/USD hedged)","BK4226":"数据处理及外包服务","LU0320765646.SGD":"FTIF - Franklin Income A MDIS SGD-H1","IAI":"iShares Dow Jones U.S. Broker De","LU1506573853.SGD":"MANULIFE GF GLOBAL EQUITY \"AA\" (SGD) INC","LU2456880835.USD":"ALLIANZ GLOBAL INCOME \"AT\" (USD) ACC","LU1366192091.USD":"ALLIANZ US EQUITY PLUS \"AM\" (USD) INC","LU2360032135.SGD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (SGDHDG) INC"},"translate_title":"Attovia Therapeutics is expected to surge on first day of Nasdaq listing after IPO expands to $289m","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TFNS":0.6,"IYF":0.6,"IAI":0.6,"FTXO":0.6,"KBWB":0.6,"MNSH":0.9,"ATTO":0.9},"content_text":"BUZZ-<a href=\"https://laohu8.com/S/ATTO\">Attovia Therapeutics</a> 在IPO規模擴大至2.89億美元后，有望在納斯達克上市首日大漲8月5日 - ** 阿托維亞治療公司（Attovia Therapeutics，股票代碼： ATTO.O）在將美國首次公開募股（IPO）規模擴大至2.89億美元后，其納斯達克首日上市開盤價有望遠高於發行價 ** 該股最新顯示開盤價為每股24美元，而IPO發行價為17美元** 總部位於加利福尼亞州聖卡洛斯的 ATTO（(link)）於周二晚間以每股17美元的價格售出1700萬股 (link)，此次IPO規模已擴大 (link) ** ATTO公司致力於研發免疫介導性疾病的治療方案，最初計劃發行約1250萬股，定價區間為每股15至17美元** 其主要研發項目包括ATTO-1310，該藥物正在開發用於治療慢性瘙癢性疾病** 摩根士丹利、Leerink Partners、花旗集團和加拿大皇家銀行資本市場擔任此次發行的聯合簿記管理人","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"shareholding,corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}